Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer

Annals of the New York Academy of Sciences

Volumn 905, Issue , 2000, Pages 188-208

  Fang, Xianjun ^a,e   Gaudette, Douglas ^a   Furui, Tatsuro ^a   Mao, Muling ^a   Estrella, Veronica ^a   Eder, Astrid ^a   Pustilnik, Terri ^a   Sasagawa, Takayo ^a   Lapushin, Ruthie ^a   Yu, Shiangxing ^a   Jaffe, Robert B ^b   Wiener, Jon R ^a   Erickson, James R ^c,d   Mills, Gordon B ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Atairgin Technologies Inc   (United States)

^d LXR Biotechnology Inc   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTOTOXIC AGENT; G PROTEIN COUPLED RECEPTOR; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; INTERLEUKIN 8; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDYLCHOLINE; MESSENGER RNA; UROKINASE; VASCULOTROPIN;

APOPTOSIS; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CELL SURVIVAL; CONFERENCE PAPER; FEMALE; HUMAN; METASTASIS; OVARY CANCER; PROGNOSIS; SIGNAL TRANSDUCTION;

FALLOPIA;

EID: 0034015046     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb06550.x     Document Type: Conference Paper

References (78)

1. 1. AMERICAN CANCER SOCIETY. 1999. Cancer Facts and Figures - 1998. Amer. Cancer Soc. Atlanta.
2. 2. VAN CORVEN, E.J., A. GROENINK, K. JALINK, T. EICHHOLTZ & W. MOOLENAAR. 1989. Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins. Cell 59: 45-54.
3. 3. MOOLENAAR, W., K. JALINK & E. VAN CORVEN. 1992. Lysophosphatidic acid: a bioactive phospholipid with growth factor-like properties. Rev. Physiol. Biochem. Pharmacol. 119: 47-65.
4. 4. MOOLENAAR, W., R. VAN DER BEND, E. VAN CORVEN, K. JALINK, T. EICHHOLTZ & W. VAN BLITTERSWIJK. 1992. Lysophosphatidic acid: a novel phospholipid with hormone and growth factor-like activities. Cold Spring Harbor Symp. Quant. Biol. 56: 163-167.
5. 5. TIGYI, G. & R. MILEDI. 1992. Lysophosphatidinates bound to serum albumin activate membrane currents in Xenopus Iaevis oocytes and neurite retraction in PC12 pheochromocytoma cells. J. Biol. Chem. 267: 21360-21367.
6. 6. AN, S., E.J. GOETZL & H. LEE. 1998. Signaling mechanisms and molecular characteristics of G protein-coupled receptors for lysophatidic acid and sphingosine 1-phosphate. J. Cell. Biochem. 30/31: 147-157.
7. 7. GOETZL, E.J. & S. AN. 1998. Diversity of cellular receptors and functions for the lysophospholipid growth factor lysophatidic acid and sphingosine 1-phosphate. FASEB J. In press.
8. 8. NIETGEN, G.W. & M.E. DURIEUX. 1998. Intercellular signaling by lysophosphatidate: recent developments. Cell Adhesions Commun. 5: 221-235.
9. 9. Xu, Y., G. CASEY & G.B. MILLS. 1995. Effect of lysophospholipids on signaling in the human Jurkat T cell line. J. Cell. Physiol. 163(3): 441-450.
10. 10. Xu, Y., X.J. FANG, G. CASEY & G.B. MILLS. 1995. Lysophospholipids activate ovarian and breast cancer cells. Biochem. J. 309: 933-940.
11. 11. Xu, Y., D. GAUDETTE, J.D. BOYNTON, A. FRANKEL, X-J. FANG, A. SHARMA, J. HURTEAU, G. CASEY, A. GOODBODY, A. MELLORS, B. HOLUB & G.B. MILLS. 1995. Characterization of an ovarian cancer activating factor (OCAF) in ascites from ovarian cancer patients. Clin. Cancer Res. 1: 1223-1232.
12. 12. LILIOM, K., D.J. FICHER, T. VIRAG et al. 1998. Identification of a novel growth factor-like lipid, 1-O-cis-alk-1′-enyl-2-lyso-sn-glycero-3-phosphate (alkenyl-GP), that is present in commercial sphingolipid preparations. J. Biol. Chem. 273(22): 13461-13468.
13. 13. GOHLA, A., R. HARHAMMER & G. SHULTZ. 1998. The G-protein G13 but not G12 mediates signaling from lysophosphatidic acid receptor via epidermal growth factor receptor to Rho. J. Biol. Chem. 273(8): 4653-4659.
14. i by lysophosphatidic acid (LPA) in wild-type and 2C10 adrenoceptor-transfected Rat 1 fibroblasts. Biochem. J. 298: 493-497.
15. 15. HORDIJK, P.L. et al. 1994. Protein tyrosine phosphorylation induced by lysophosphatidic acid in Rat-1 fibroblasts. J. Biol. Chem. 269: 645-651.
16. raf-1. J. Biol. Chem. 268: 20717-20720.
17. 17. SEUFFERLEIN, T. & E.L. ROZENGURT. 1994. Lysophosphatidic acid stimulates tyrosine phosphorylation of focal adhesion kinase, paxillin, and p130. J. Biol. Chem. 269: 9345-9351.
18. 18. HILL, C.S., J. WYNNE & R. TREISMAN. 1995. The Rho family GTPases RhoA, Rac1, and CDC42Hs regulate transcriptional activation by SRF. Cell 81(7): 1159-1170.
19. 19. HART, M.J., X. JIANG, T. KOZASA et al. 1998. Direct stimulation of the guanine nucleotide exchange activity of p115 RhoGEF by Galpha13. Science 280(5372): 2112-2114.
20. 20. KOZASA, T., X. JIANG, M.J. HART et al. 1998. p115 RhoGEF, a GTPase activating protein for Galpha12 and Galpha13. Science 280(5372): 2109-2111.
21. 21. BELTMAN, J., J.R. ERICKSON, G.A. MARTIN et al. 1999. C3 toxin activates the stress signaling pathways, JNK and p38, but antagonizes the activation of AP-1 in Rat-1 cells. J. Biol. Chem. 274(6): 3772-3780.
22. 22. DELLA ROCCA, G.J., S. MAUDSLEY, Y. DAAKA et al. 1999. Pleiotropic coupling of G protein-coupled receptors to the mitogen-activated protein kinase cascade: role of focal adhesions and receptor tyrosine kinases. J. Biol. Chem. 274(20): 13978-13984.
23. 23. COOK, T.A., T. NAGASAKI & G.G. GUNDERSEN. 1998. Rho guanosine triphosphatase mediates the selective stabilization of microtubules induced by lysophosphatidic acid. J. Cell Biol. 141(1): 175-185.
24. 24. KELVIN, D.J. et al. 1993. Chemokines and serpentines: the molecular biology of chemokine receptors. J. Leukocyte Biol. 54: 604-612.
25. 25. SAVARESE, T.M. & C.M. FRASER. 1992. In vitro mutagenesis and the search for structure-function relationships among G protein-coupled receptors. Biochem. J. 283: 1-19.
26. 26. GUO, Z., K. LILIOM, D.J. FISCHER et al. 1996. Molecular cloning of a high-affinity receptor for the growth factor-like lipid mediator lysophosphatidic acid from Xenopus oocytes. Proc. Natl. Acad. Sci. U.S.A. 93(25): 14367-14372.
27. 27. HECHT, J.H., J.A. WEINER, S.R. POST et al. 1996. Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J. Cell Biol. 135(4): 1071-1083.
28. 28. AN, S., T. BLEU, O.G. HALLMARK et al. 1998. Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J. Biol. Chem. 273(14): 7906-7910.
29. 29. FUKUSHIMA, N., Y. KIMURA & J. CHUN. 1998. A single receptor encoded by vzg-1/ lpA1/edg-2 couples to G proteins and mediates multiple cellular responses to lysophosphatic acid. Proc. Natl. Acad. Sci. U.S.A. 95(11): 6151-6156.
30. 30. LEE, M.J., S. THANGADA, C.H. LIU et al. 1998. Lysophosphatidic acid stimulates the G-protein-coupled receptor EDG-1 as a low affinity agonist. J. Biol. Chem. 273(34): 22105-22112.
31. 31. ZONDAG, G.C., F.R. POSTMA, I.V. ETTEN et al. 1998. Sphingosine 1-phosphate signaling through the G-protein-coupled receptor Edg-1. Biochem. J. 330(part 2): 605-609.
32. 32. GRALER, M.H., G. BERNHARDT & M. LIPP. 1998. EDG6, a novel G-protein-coupled receptor related to receptors for bioactive lysophospholipids, is specifically expressed in lymphoid tissue. Genomics 53: 164-169.
33. 33. ZHANG, G., J.J. CONTOS, J.A. WEINER et al. 1999. Comparative analysis of three murine G-protein coupled receptors activated by sphingosine-1-phosphate. Gene 277: 89-99.
34. 34. ERICKSON, J.R., J.J. WU, J.G. GODDARD et al. 1998. Edg-2/Vzg-1 couples to the yeast pheromone response pathway selectively in response to lysophosphatidic acid. J. Biol. Chem. 273(3): 1506-1510.
35. 35. LEE, M.J., J.R. VAN BROCKLYN, S. THANGADA et al. 1998. Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science 279(5356): 1552-1555.
36. 36. VAN BROCKLYN, J.R., M.J. LEE, R. MENZELEEV et al. 1998. Dual actions of sphingosine-1-phosphate: extracellular through the Gi-coupled receptor Edg-1 and intracellular to regulate proliferation and survival. J. Cell Biol. 142(1): 229-240.
37. 37. FISCHER, D.J., K. LILIOM, Z. GUO et al. 1998. Naturally occurring analogs of lysophosphatidic acid elicit different cellular responses through selective activation of multiple receptor subtypes. Mol. Pharmacol. 54: 979-988.
38. 38. AN, S., T. BLEU, Y. ZHENG et al. 1998. Recombinant human G protein-coupled lysophosphatidic acid receptors mediate intracellular calcium mobilization. Mol. Pharmacol. 54: 881-888.
39. 39. VAN CORVEN, E.J., A. VAN RIJSWIJK, K. JALINK et al. 1992. Mitogenic action of lysophosphatidic acid and phosphatidic acid on fibroblasts: dependence on acyl-chain length and inhibition by suramin. Biochem. J. 281(part 1): 163-169.
40. 40. SULLIVAN, L.M., C.W. HONEMANN, J.A. ARLEDGE et al. 1999. Synergistic inhibition of lysophosphatidic acid signaling by charged and uncharged local anesthetics. Anesth. Analg. 88(5): 1117-1124.
41. 41. LILIOM, K., R. BITTMAN, B. SWORDS et al. 1996. N-Palmitoyl-serine and N-palmitoyl-tyrosine phosphoric acids are selective competitive antagonists of the lysophosphatidic acid receptors. Mol. Pharmacol. 50(3): 616-623.
42. 42. MURAKAMI-MUROFUSHI, K., K. KAJI, K. KANO et al. 1993. Inhibition of cell proliferation by a unique lysophosphatidic acid, PHYLPA, isolated from Physarum polycephalum: signaling events of antiproliferation action by PHYLPA. Cell Struct. Funct. 18(5): 363-370.
43. 43. SHEN, Z., J. BELINSON, R.E. MORTON et al. 1998. Phorbol 12-myristate 13-acetate stimulates lysophosphatidic acid secretion from ovarian and cervical cancer cells, but not from breast or leukemia cells. Gynecol. Oncol. 71(3): 364-368.
44. 44. EICHHOLTZ, T. et al. 1993. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem. J. 291: 677-680.
45. 45. GERRARD, J.M. & P. ROBINSON. 1989. Identification of the molecular species of lysophosphatidic acid produced when platelets are stimulated by thrombin. Biochim. Biophys. Acta 1001: 282-285.
46. 46. TOKUMURA, A., Y. NISHIOKA, O. YOSHIMOTO et al. 1999. Substrate specificity of lysophosphatidic D which produces bioactive lysophosphatidic acid in rat plasma. Biochim. Biophys. Acta 1437(2): 235-245.
47. 2 and of lysophosphatidic acid synthesis. Adv. Enzyme Regul. 38: 99-107.
48. 48. SAKAI, M., A. MIYAZAKI, H. HAKAMATA, T. SAKAKI et al. 1994. Lysophosphatidylcholine plays an essential role in the mitogenic effect of oxidized low density lipoprotein on murine macrophages. J. Biol. Chem. 269: 31430-31435.
49. 49. LOCHER, R., B. WEISSER, T. MENGDEN, C. BRUNNER & W. VETTER. 1992. Lysolecithin actions on vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 183: 156-162.
50. 50. SATO, N., K. KOICHI, K. SHIMOKADO et al. 1998. Changes of gene expression by lysophosphatidylcholine in vascular endothelial cells: 12 up-regulated distinct genes including 5 cell growth-related, 3 thrombosis-related, and 4 others. J. Biochem. 123: 1119-1126.
51. 51. KUME, N., M.I. CYBULSKY & M.A. GIMBRONE. 1992. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J. Clin. Invest. 90(3): 1138-1144.
52. 52. MILLS, G.B., C. MAY, M. MCGILL, C. ROIFMAN & A. MELLORS. 1988. A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res. 48: 1066-1071.
53. 53. MILLS, G.B., C. MAY, M. HILL, S. CAMPBELL, P. SHAW & A. MARKS. 1990. Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian cancer cells. J. Clin. Invest. 86: 851-855.
54. 54. WESTERMANN, A.M., E. HAVIK, F.R. POSTMA, J.H. BEIJNEN, O. DALESIO, W.H. MOOLENAAR & S. RODENHUIS. 1998. Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann. Oncol. 9(4): 437-442.
55. 55. FANG, X-J., R. LAPUSHIN, Y. LU, T. FURUI, L.Z. PENN, D.F. STOKOE, R.C. BAST & G.B. MILLS. 1999. Lysophosphatidic acid prevents apoptosis in fibroblasts: dissection of proliferative and survival signals. Submitted.
56. 56. FRANKEL, A. & G.B. MILLS. 1996. Peptide and lipid growth factors decrease cisplatin-induced cell death in human ovarian cancer cells. Clin. Cancer Res. 2: 1307-1313.
57. 57. HU, Y-L., E.J. GOETZL, G.B. MILLS, N. FERRARA & R.B. JAFFE. 1999. Induction of vascular endothelial growth factor expression by lysophosphatidic acid in normal and neoplastic human ovarian epithelial cells. Submitted.
58. 58. PUSTILNIK, T.B., V. ESTRELLA, J. WIENER, M.A. WATT, D. BOYD, R.C. BAST & G.B. MILLS. 1999. LPA induces urokinase secretion in ovarian cancer cells. Submitted.
59. MAPK pathway. Submitted.
60. 60. Xu, Y., X. FANG, T. FURUI, T. SASAGAWA, T. PUSTILNIK, Y. LU, Z. SHEN, J.R. WIENER, L. SHAYESTEH, J.W. GRAY, R.C. BAST, JR. & G.B. MILLS. 1998. Regulation of growth of ovarian cancer cells by phospholipid growth factors. In Ovarian Cancer 5. pp. 109B-120B. ISIS Medical Media. Oxford.
61. 61. FANG, X.J., S. GIBSON, M. FLOWERS, T. FURUI, R.C. BAST & G.B. MILLS. 1997. Lysophosphatidylcholine stimulates AP-1 and the c-Jun N-terminal kinase activity. J. Biol. Chem. 272: 13683-13689.
62. 62. FRISCH, S.M. & E. RUOSLAHTI. 1997. Integrins and anoikis. Curr. Opin. Cell Biol. 9: 701-706.
63. 63. VALENTINIS, B., K. REISS & R. BASERGA. 1998. Insulin-like growth factor-I-mediated survival from anoikis: role of cell aggregation and focal adhesion kinase. J. Cell. Physiol. 176(3): 648-657.
64. 64. FRISCH, S.M. & H. FRANCIS. 1994. Disruption of epithelial cell-matrix interactions induces apoptosis. J. Cell Biol. 124(4): 619-626.
65. 65. FRISCH, S.M., K. VUORI, E. RUOSLAHTI & P.Y. CHAN-HUI. 1996. Control of adhesion-dependent cell survival by focal adhesion kinase. J. Cell Biol. 134(3): 793-799.
66. 66. FURUI, T., R. LAPUSHIN, M. MAO, H. KAHN, S.R. WATT, M.V. WATT, Y. LU, X. FANG, S. TSUTUSI, Z. SIDDIK, R.C. BAST & G.B. MILLS. 1999. Overexpression of Edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid independent manner. Clin. Cancer Res. In press.
67. 67. YOSHIDA, A. & H. UEDA. 1999. Activation of Gi1 by lysophosphatidic acid receptor without ligand in the baculovirus expression system. Biochem. Biophys. Res. Commun. 259(1): 78-84.
68. 68. VAN GALEN, P.J.M., G.L. STILES, G. MICHAELS & K.A. JACOBSON. 1992. Adenosine A1 and A2 receptors: structure-function relationships. Med. Res. Rev. 12: 423-471.
69. 69. KOSUGI, S. & T. MORI. 1994. The third exoplasmic loop of the thyrotropin receptor is partially involved in signal transduction. FEBS Lett. 349: 89-92.
70. 70. PIN, J.P., J. GOMEZA, C. JOLY & J. BOCKAERT. 1995. The metabotropic glutamate receptors: their second intracellular loop plays a critical role in the G-protein coupling specificity. Biochem. Soc. Trans. 23: 91-96.
71. 71. LATTION, A.L., D. DIVIANI & S. COTECCHIA. 1994. Truncation of the receptor carboxyl terminus impairs agonist-dependent phosphorylation and desensitization of the alpha 1B-adrenergic receptor. J. Biol. Chem. 269: 22887-22893.
72. 72. PARENT, J.L., C.L. GOUILL, M. ROLA-PLESZCZYNSKI & J. STANKOVA. 1996. Mutation of an aspartate at position 63 in the human platelet-activating factor receptor augments binding affinity, but abolishes G protein coupling and inositol phosphate production. Biochem. Biophys. Res. Commun. 219: 968-975.
73. 73. SHAYESTEH, L., Y. LU, W.L. KUO, R. BALDOCCHI, T. GODFREY, C. COLLINS, D. PINKEL, B. POWELL, G.B. MILLS & J.W. GRAY. 1999. PIK3CA is implicated as an oncogene in ovarian cancer. Nature Genet. 21: 99-102.
74. 74. XU, Y., Z. SHEN, D.W. WIPER, M. WU, R.E. MORTON, P. ELSON, A.W. KENNEDY, J. BELINSON, M. MARKMAN & G. CASEY. 1998. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 280(8): 719-723.
75. 75. BAST, R.C., F. XU, Y. YU, S. BARNHILL, Z. ZHANO & G.B. MILLS. 1998. CA125: the past and the future. Int. J. Biol. Markers 13: 179-187.
76. 76. SASAGAWA, T., K. SUZUKI, T. SHIOTA, T. KONDO & M. OKITA. 1998. The significance of plasma lysophospholipids in patients with renal failure on hemodialysis. J. Nutr. Sci. Vitaminol. (Tokyo) 44(6): 809-818.
77. 77. SASAGAWA, T., M. OKITA, J. MURAKAMI, T. KATO & A. WATANABE. 1999. Abnormal serum lysophospholipids in multiple myeloma patients. Lipids 34(1): 17-21.
78. 78. OKITA, M., D.C. GAUDETTE, G.B. MILLS & B.J. HOLUB. 1997. Elevated levels of plasma lysophosphatidylcholine (LysoPC) in ovarian cancer patients. Int. J. Cancer 71:31-34.